-
1 Comment
ANI Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
ANI Pharmaceuticals, Inc's total revenue rose by 19.4% to $57M since the same quarter in the previous year.
Its net income has increased by 24.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 328.3% to $-8M since the same quarter in the previous year.
Based on the above factors, ANI Pharmaceuticals, Inc gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US00182C1036 |
| Beta | 0.49 |
|---|---|
| Market Cap | 2B |
| PE Ratio | None |
| Target Price | 81.875 |
| Dividend Yield | None |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ANIP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
